Literature DB >> 9219507

Dose intensity of uracil and tegafur in postoperative chemotherapy for patients with poorly differentiated gastric cancer.

K Sugimachi1, Y Maehara, M Ogawa, T Kakegawa, M Tomita.   

Abstract

A retrospective analysis of postoperative chemotherapy had shown the continuous administration of UFT, an oral preparation of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) and uracil at a molar ratio of 1:4, to be effective for poorly differentiated gastric cancer. We therefore sought to determine prospectively the effective dose of postoperative chemotherapy with UFT for patients with poorly differentiated gastric cancer following a curative resection. We determined the effect of the combined intravenous administration of mitomycin C (MMC) and oral treatment with protein-bound polysaccharide Kreha (PSK), extracted from the basidiomycete Coriolus versicolor, and UFT at a dose of either 8 mg/kg or 12 mg/kg daily for 1 year. A total of 224 patients with poorly differentiated stage II-IV gastric cancer were entered into this study after undergoing a curative resection. No differences were observed between the two treatment groups in terms of prognostic factors, the toxicity rate or the doses of the drugs prescribed, other than UFT. The higher dose of UFT in maintenance therapy led to a decrease in the recurrence rate (P < 0.05), and increases in disease-free survival and cause-specific survival (P < 0.05). UFT at 12 mg/kg in postoperative chemotherapy was thus found- to improve the postoperative results with no increase in toxicity for poorly differentiated gastric cancer, and is also cost-effective for outpatients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9219507     DOI: 10.1007/s002800050652

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  7 in total

1.  Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery.

Authors:  Toshiro Okuyama; Daisuke Korenaga; Ai Edagawa; Shinji Itoh; Eiji Oki; Hirofumi Kawanaka; Yasuharu Ikeda; Yoshihiro Kakeji; Masahiro Tateishi; Shunichi Tsujitani; Kenji Takenaka; Yoshihiko Maehara
Journal:  Surg Today       Date:  2012-01-27       Impact factor: 2.549

Review 2.  Trametes versicolor mushroom immune therapy in breast cancer.

Authors:  Leanna J Standish; Cynthia A Wenner; Erin S Sweet; Carly Bridge; Ana Nelson; Mark Martzen; Jeffrey Novack; Carolyn Torkelson
Journal:  J Soc Integr Oncol       Date:  2008

Review 3.  Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN(®)): review of development and future perspectives.

Authors:  Yoshihiko Maehara; Shunichi Tsujitani; Hiroshi Saeki; Eiji Oki; Keiji Yoshinaga; Yasunori Emi; Masaru Morita; Shunji Kohnoe; Yoshihiro Kakeji; Tokujiro Yano; Hideo Baba
Journal:  Surg Today       Date:  2011-12-06       Impact factor: 2.549

4.  An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer.

Authors:  J Sakamoto; C Hamada; S Yoshida; S Kodaira; M Yasutomi; T Kato; K Oba; H Nakazato; S Saji; Y Ohashi
Journal:  Br J Cancer       Date:  2007-03-20       Impact factor: 7.640

5.  Prognostic value of p53 protein expression for patients with gastric cancer--a multivariate analysis.

Authors:  Y Maehara; M Tomoda; S Hasuda; A Kabashima; E Tokunaga; Y Kakeji; K Sugimachi
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

Review 6.  Herb-drug interactions between the medicinal mushrooms Lingzhi and Yunzhi and cytotoxic anticancer drugs: a systematic review.

Authors:  Chun Sing Lam; Lok Pui Cheng; Li Min Zhou; Yin Ting Cheung; Zhong Zuo
Journal:  Chin Med       Date:  2020-07-25       Impact factor: 5.455

7.  Synthesis of new 1,2,3-triazole derivatives of uracil and thymine with potential inhibitory activity against acidic corrosion of steels.

Authors:  Guillermo E Negrón-Silva; Rodrigo González-Olvera; Deyanira Angeles-Beltrán; Nidia Maldonado-Carmona; Araceli Espinoza-Vázquez; Manuel E Palomar-Pardavé; Mario A Romero-Romo; Rosa Santillan
Journal:  Molecules       Date:  2013-04-18       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.